Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01615705 · ClinicalTrials.gov registry record
Biomarker Sub Study of the Compression Stockings to Prevent the Post-Thrombotic Syndrome (SOX) Trial
A clinical trial, sponsored by Sir Mortimer B. Davis - Jewish General Hospital.
- Completed
- Registry status
- 803
- Enrollment target
NCT01615705: Completed study, sponsored by Sir Mortimer B. Davis - Jewish General Hospital.
NCT01615705 is a clinical trial that has completed, run by Sir Mortimer B. Davis - Jewish General Hospital. The registered enrollment target is 803 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01615705 has completed, sponsored by Sir Mortimer B. Davis - Jewish General Hospital.
- COMPLETED
- Registry status
- 803 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate whether biomarkers of inflammation, genetic thrombophilia and coagulation activation influence Post-Thrombotic Syndrome development in patients with symptomatic proximal deep venous thrombosis.
Primary Outcome
Blood samples drawn at baseline, 1 and 6-mths to evaluate the relationship between CRP, ICAM, IL-6, IL-10 with the subsequent development of PTS.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 803 participants |
| Start Date | 2004-06 |
| Est. Completion | 2012-02 |
What the finished NCT01615705 record still lists
NCT01615705 is an observational study that tracks outcomes without assigning an intervention. The registered 803 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT01615705 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01615705 about?
NCT01615705 is a clinical study titled "Biomarker Sub Study of the Compression Stockings to Prevent the Post-Thrombotic Syndrome (SOX) Trial". The purpose of this study is to evaluate whether biomarkers of inflammation, genetic thrombophilia and coagulation activation influence Post-Thrombotic Syndrome development in patients with symptomatic proximal deep venous thrombosis.
What is the current status of trial NCT01615705?
This trial is currently completed. The enrollment target is 803 participants. The study started on 2004-06. Estimated completion is 2012-02.
Who is sponsoring clinical trial NCT01615705?
This trial is sponsored by Sir Mortimer B. Davis - Jewish General Hospital, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04423211 · 804 participants · Phase 3
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
- NCT06522022 · 804 participants · NA
PTSD Screening in Pregnant Black Women
- NCT03524430 · 801 participants · NA
RNA Disruption Assay (RDA)-Breast Cancer Response Evaluation for Individualized Therapy
- NCT04613596 · 806 participants · Phase 2
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia